Plain-English translation of NCT07205874 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking for early warning signs of primary biliary cholangitis (PBC), a disease that affects the liver. Researchers want to understand which patients with specific antibodies in their blood—even when other blood tests look normal—actually have PBC. To do this, they will collect blood samples and perform a liver biopsy (a small tissue sample taken from the liver) to see who has the disease.
PBC can develop slowly and cause serious liver damage over time. Right now, doctors struggle to identify patients in the very early stages when the disease hasn't yet shown up in standard blood tests. Finding these patients earlier could help them start treatment sooner and prevent complications.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood tests done and undergo a liver biopsy—a procedure where doctors use a thin needle to take a small sample of liver tissue for examination. The biopsy helps doctors see if PBC is present even when blood tests appear normal. Researchers will follow your health information to understand which features predict who develops this disease, helping them identify patients earlier in the future.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
Spain
Sponsor
Hospital Universitario La Paz
Enrollment target
~80 participants
Started
September 2025
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in October 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.